RevolKa Started joint research of a drug discovery program for rare diseases

Tokyo Japan- Aug 6th, 2024. RevolKa Ltd. (Norio Hamamatsu, CEO) has signed a joint research agreement with a medical research institution regarding rare diseases. Utilizing the synergy between RevolKa’s innovative drug candidates created by the game-changing AI-powered protein engineering technology called aiProtein® and the pharmaceutical research and development capabilities of the medical research institution, we will jointly begin research and development of groundbreaking treatments for congenital rare diseases for which no treatment is available.